Abstract
Receptor Tyrosine Kinases class I (RTK class I, EGF receptor family) constitute a family of transmembrane proteins involved in various aspects of cell growth and survival and have been implicated in the initiation and progression of several types of human malignancies. Activation of EGFR may be because of overexpression, mutations resulting in constitutive activation, or autocrine expression of ligand. In contrast, activation of HER2 occurs mainly by overexpression, which leads to spontaneous homodimerization and activation of downstream signaling events in a ligandindependent manner. EGFR and HER2 have now been validated as a clinically relevant target, and several different types of agents inhibiting these receptors are currently in development. The EGFR inhibitors Erlotinib, Gefitinib, and Cetuximab have undergone extensive clinical testing and have established clinical activity in non small cell lung cancer (NSCLS) and other types of solid tumors. Several of the other erbB inhibitors are also undergoing advanced clinical testing, either alone or in combination with other agents. This review reports various inhibitors, natural, small molecules and monoclonal antibodies, along with their reported activities for various members of erbB family. It will highlight the potential for the development of novel anti-cancer molecules.
Keywords: Receptor tyrosine kinase, erbB, EGFR, HER2, small molecule inhibitors, monoclonal antibodies, breast cancer, anticancer agents
Current Pharmaceutical Design
Title: Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Volume: 15 Issue: 7
Author(s): P. Sapra Sharma, R. Sharma and T. Tyagi
Affiliation:
Keywords: Receptor tyrosine kinase, erbB, EGFR, HER2, small molecule inhibitors, monoclonal antibodies, breast cancer, anticancer agents
Abstract: Receptor Tyrosine Kinases class I (RTK class I, EGF receptor family) constitute a family of transmembrane proteins involved in various aspects of cell growth and survival and have been implicated in the initiation and progression of several types of human malignancies. Activation of EGFR may be because of overexpression, mutations resulting in constitutive activation, or autocrine expression of ligand. In contrast, activation of HER2 occurs mainly by overexpression, which leads to spontaneous homodimerization and activation of downstream signaling events in a ligandindependent manner. EGFR and HER2 have now been validated as a clinically relevant target, and several different types of agents inhibiting these receptors are currently in development. The EGFR inhibitors Erlotinib, Gefitinib, and Cetuximab have undergone extensive clinical testing and have established clinical activity in non small cell lung cancer (NSCLS) and other types of solid tumors. Several of the other erbB inhibitors are also undergoing advanced clinical testing, either alone or in combination with other agents. This review reports various inhibitors, natural, small molecules and monoclonal antibodies, along with their reported activities for various members of erbB family. It will highlight the potential for the development of novel anti-cancer molecules.
Export Options
About this article
Cite this article as:
Sharma Sapra P., Sharma R. and Tyagi T., Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers, Current Pharmaceutical Design 2009; 15 (7) . https://dx.doi.org/10.2174/138161209787582219
DOI https://dx.doi.org/10.2174/138161209787582219 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Metabolizing Enzymes Mechanisms and Functions
Current Drug Metabolism The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Cellular Targets for Anticancer Strategies
Current Drug Targets MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance
Current Medicinal Chemistry Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Podophyllotoxin: Current Perspectives
Current Bioactive Compounds DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Marine Sponges: Potential Sources of New Antimicrobial Drugs
Current Pharmaceutical Biotechnology New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Medicinal Chemistry Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery On the Epistemological Crisis in Genomics
Current Genomics